We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tandem Diabetes Wins FDA's iAGC Designation for Basal-IQ
Read MoreHide Full Article
Tandem Diabetes Care, Inc. (TNDM - Free Report) recently received the FDA approval for its Basal-IQ technology to be used as an interoperable automated glycemic controller (iAGC). Earlier in December, the company, for the first time, received the iAGC designation for its t:slim X2 insulin pump with Control-IQ technology following the FDA approval.
Going by FDA’s classification, there are three categories based on the interoperability of an insulin pump device as a complete automated insulin dosing (AID) system. These are an alternate controller-enabled insulin pump (ACE pump), an integrated continuous glucose monitor (iCGM) and an iAGC. While Basal-IQ technology gets the iAGC designation, the t:slim X2 insulin pump was the first to receive an ACE infusion pump classification last February. In June 2018, this was the first insulin pump being designated to be compatible with iCGM devices.
The latest regulatory clearance is expected to boost Tandem Diabetes’ global pump shipments and expand its customer base.
More About Basal-IQ Technology
Tandem Diabetes’ t:slim X2 insulin pump with Basal-IQ technology uses a predictive low-glucose suspend algorithm which utilizes sensor values from an integrated Dexcom G6 continuous glucose monitor to help lessen the frequency and duration of low-glucose events (hypoglycemia).
One major advantage of the Basal-IQ technology is efficiency in forecasting and preventing low-glucose events, as well as no requirement of finger sticks or complicated settings.
One of the unique features of the t:slim X2 insulin pump is that it has greater insulin holding capacity despite being smaller in structure.
Market Prospects
Per Market Research Future, the global insulin market is expected to see a CAGR of 8.4% and reach a worth of $8.52 billion by 2023.
Recent Developments
Lately, Tandem Diabetes has made a major development, which has boosted the application of the t:slim X2 insulin pump.
Last December, the company received FDA clearance for the t:slim X2 insulin pump with Control-IQ technology. This is the first FDA-cleared system to deliver automatic correction boluses, along with adjusting insulin to help prevent high and low blood sugar.
In September 2019, it received Health Canada approval for the t:slim X2 insulin pump with Basal-IQ technology. With this, starting from February 2020, all in-warranty t:slim X2 pump users in Canada now have the option to integrate Basal-IQ technology to their existing pump free of cost via remote software update.
Price Performance
Shares of this company have surged 15.2% in a year, as against the industry’s 4.5% decline.
Zacks Rank and Key Picks
Tandem Diabetes currently carries a Zacks Rank # 3 (Hold).
A few better-ranked stocks from the broader medical space are ResMed (RMD - Free Report) , Medtronic (MDT - Free Report) and Hill-Rom Holdings .
Medtronic’s long-term earnings growth rate is projected at 7.4%. The company presently carries a Zacks Rank of 2.
Hill-Rom’s long-term earnings growth rate is estimated at 11.1%. It carries a Zacks Rank #2, currently.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Tandem Diabetes Wins FDA's iAGC Designation for Basal-IQ
Tandem Diabetes Care, Inc. (TNDM - Free Report) recently received the FDA approval for its Basal-IQ technology to be used as an interoperable automated glycemic controller (iAGC). Earlier in December, the company, for the first time, received the iAGC designation for its t:slim X2 insulin pump with Control-IQ technology following the FDA approval.
Going by FDA’s classification, there are three categories based on the interoperability of an insulin pump device as a complete automated insulin dosing (AID) system. These are an alternate controller-enabled insulin pump (ACE pump), an integrated continuous glucose monitor (iCGM) and an iAGC. While Basal-IQ technology gets the iAGC designation, the t:slim X2 insulin pump was the first to receive an ACE infusion pump classification last February. In June 2018, this was the first insulin pump being designated to be compatible with iCGM devices.
The latest regulatory clearance is expected to boost Tandem Diabetes’ global pump shipments and expand its customer base.
More About Basal-IQ Technology
Tandem Diabetes’ t:slim X2 insulin pump with Basal-IQ technology uses a predictive low-glucose suspend algorithm which utilizes sensor values from an integrated Dexcom G6 continuous glucose monitor to help lessen the frequency and duration of low-glucose events (hypoglycemia).
One major advantage of the Basal-IQ technology is efficiency in forecasting and preventing low-glucose events, as well as no requirement of finger sticks or complicated settings.
One of the unique features of the t:slim X2 insulin pump is that it has greater insulin holding capacity despite being smaller in structure.
Market Prospects
Per Market Research Future, the global insulin market is expected to see a CAGR of 8.4% and reach a worth of $8.52 billion by 2023.
Recent Developments
Lately, Tandem Diabetes has made a major development, which has boosted the application of the t:slim X2 insulin pump.
Last December, the company received FDA clearance for the t:slim X2 insulin pump with Control-IQ technology. This is the first FDA-cleared system to deliver automatic correction boluses, along with adjusting insulin to help prevent high and low blood sugar.
In September 2019, it received Health Canada approval for the t:slim X2 insulin pump with Basal-IQ technology. With this, starting from February 2020, all in-warranty t:slim X2 pump users in Canada now have the option to integrate Basal-IQ technology to their existing pump free of cost via remote software update.
Price Performance
Shares of this company have surged 15.2% in a year, as against the industry’s 4.5% decline.
Zacks Rank and Key Picks
Tandem Diabetes currently carries a Zacks Rank # 3 (Hold).
A few better-ranked stocks from the broader medical space are ResMed (RMD - Free Report) , Medtronic (MDT - Free Report) and Hill-Rom Holdings .
ResMed has an estimated long-term earnings growth rate of 12%. It currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Medtronic’s long-term earnings growth rate is projected at 7.4%. The company presently carries a Zacks Rank of 2.
Hill-Rom’s long-term earnings growth rate is estimated at 11.1%. It carries a Zacks Rank #2, currently.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>